Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...

Service members encounter a wide range of both rewarding and demanding experiences throughout their careers. Some unique ...

Delhi High Court bars Dr Reddy's and OneSource from selling semaglutide in India, supporting Novo Nordisk's patent rights as ...

Dr Reddy's Laboratories had received the manufacturing licence for semaglutide in December 2024 and it began production in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Corban OneSource empowers teams with accurate, compliant payroll solutions that save time, reduce risk, and enable smarter, people-focused decisions CLEARWATER, FL, UNITED STATES, May 27 ...

Dr. Reddy’s and OneSource agree not to sell Novo Nordisk’s anti-obesity drug in India amid patent infringement lawsuit.

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...

The court’s intervention comes at a crucial time as Novo Nordisk gears up for the rollout of Wegovy, amid rising global ...

The undertaking to Delhi HC follows a patent infringement plea filed by the Danish drugmaker against Dr Reddy’s Laboratories ...

Further, the name of the Company has been changed from Stelis Biopharma Limited to OneSource Specialty Pharma Limited effective February 13, 2024. The Company did not make any profits during the ...